Baseimmune Secures £9M in Series A to Propel AI-Driven Vaccine Development Against Major Diseases.
Baseimmune is leveraging AI for vaccine development.
Company Name: Baseimmune
Location: London, UK
Sector: Biotechnology / AI-Powered Vaccine Design
Funding Details: Raised £9M in Series A funding, led by MSD Global Health Innovation Fund and IQ Capital, with participation from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc.
Purpose of Investment: To accelerate the development of vaccine candidates for African swine fever, coronavirus, and malaria, enhance technology, expand the team, and speed up new vaccine programs.
Leadership: Co-founders Joshua Blight and Ariane Gomes
Product: An AI-powered vaccine design algorithm that integrates various data types to create synthetic proteins for inducing protective immune responses. This approach aims to develop cross-protective, “future-proof” vaccines compatible with multiple technology platforms.
About Company: Baseimmune is leveraging AI for vaccine development. Its platform analyzes a vast array of data to predict future pathogen mutations, enabling the creation of novel vaccines designed to protect against both current and emergent strains.
